Small Cap Traders makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Special Profile* - Two Clinical Stage Products Lead the Way in a Promising Pipeline and Large

Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM), (“the company”) is a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company develops cancer drugs, primarily using its Alpha Particle Immunotherapy Technology (“APIT) platform. This patented technology combines monoclonal antibodies (mAB) for targeting specific types of cells with alpha emitting radioisotopes (actinium-225 and bismuth-213), and specific beta emitting radiopharmaceuticals, to precisely target and kill cancerous cells. The Company’s products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC).

Company Highlights
  • -Completed secondary offering, resulting in approximately $18.4 million in proceeds.
    -Attained Orphan-Drug Status for Actimab™-A.
    -Announced filing for Investigational New Drug meeting with U.S. FDA to finalize development of Iomab™-B.
    -Prepared for Phase 3 Trial of Iomab™-B and Phase 2 Trial of Actimab™-A by mid-year 2015.
    -Merck a leading drug manufacturer holds a large position in company. (Makin ATNM a Possible Acquisition Target)
For a full analyst report on ATNM that includes a company overview, market and competition breakdown, recent events, outlook, valuation, analyst summary and recommendation can be viewed by using the following link at no cost: http://bit.ly/--ATNM--AnalystReport

Text "SmallCap" to 25827 to receive alerts quicker

4 Brief Company Reports:

FXCM, Inc. (NYSE: FXCM) is a leading provider of online foreign exchange (forex) trading, CFD trading, spread betting and related services.

The company is acquiring a majority of CitiFX Pro margin accounts, selling FXCM Asia Limited, and has released information on its recent quarter’s financial result. You can read about these developments here: http://bit.ly/_FXCM_AnalystReport

Hasbro, Inc. (NASDAQ: HAS) is a global company leveraging its brands, including LITTLEST PET SHOP, MAGIC: THE GATHERING, MONOPOLY, MY LITTLE PONY, NERF and PLAY-DOH.

The company has advised a cash dividend to be paid on common shares and has recently been ranked as one of America’s most reputable companies. Read about these developments in the report you will find here: http://bit.ly/_HAS_AnalystReport

Intelliphamaceutics International, Inc. (NASDAQ: IPCI) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.

The company has requested Fast Track designation for its oxycodone extended release tablets. Get the details of the drug and its status in the report provided at the link: http://bit.ly/_IPCI_AnalystReport

Valmie Resources, Inc. (OTCBB: VMRI) is pursuing opportunities in the technology industry. Valmie focuses on advanced unmanned aerial vehicle (UAV) software, hardware and cloud services for a wide range of commercial applications.

The company has released a thorough update to shareholders covering a wide array of topics, as well as announcing an upcoming trip to China. Read it here in the report that follows: http://bit.ly/_VMRI_AnalystReport

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this report have not been compensated in any form by the profiled company or any related party.  A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company. We have not been compensated in any form for these reports.
For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcaptraders.com. For any urgent concerns or inquiries please contact us at editor@smallcaptraders.com.

Source: Small Cap Traders
Contact: editor@smallcaptraders.com
                         
 

Valmie Res (CE) (USOTC:VMRI)
Historical Stock Chart
From Mar 2025 to Apr 2025 Click Here for more Valmie Res (CE) Charts.
Valmie Res (CE) (USOTC:VMRI)
Historical Stock Chart
From Apr 2024 to Apr 2025 Click Here for more Valmie Res (CE) Charts.